The tumor-suppressing protein p53 has long been considered a valuable target—if only drug hunters could figure out how to hit it. Many research efforts aiming to leverage the capabilities of this ...
PC14586 is a first-in-class, small molecule, p53 reactivator designed to selectively bind to the crevice present in the p53 Y220C mutant protein, hence, restoring the wild-type, or normal, p53 protein ...
Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new ChairPRINCETON, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV ...
PMV Pharmaceuticals, Inc. reported a corporate update and financial results for the first quarter of 2025, focusing on the ongoing Phase 2 PYNNACLE clinical trial evaluating rezatapopt, a treatment ...
PMV Pharmaceuticals Inc.’s rezatapopt yielded impressive overall response data in ovarian cancer, prompting the firm to aim for a potential accelerated approval filing in early 2027. The news caused ...
New Jersey oncology biotech PMV Pharma has seen a healthy $74 million in funding from its Series B with help from InterWest Partners, Osage University Partners, Topspin Biotech Fund (which led this ...
Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancerNew ...
PMV Electric says that their first car will get a digital infotainment system and a USB charging port(PMV) 0 PMV, a Mumbai based electric vehicle manufacturer, is all set to launch its micro-electric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results